Post by Idorsia Pharmaceuticals Ltd

Today, Idorsia announced the appointment of Roland Wandeler as Chief Executive Officer, effective October 1, 2026. Roland brings more than 25 years of global biopharmaceutical leadership experience spanning both large pharmaceutical organizations and entrepreneurial biotechs, with a unique combination of scientific expertise and business acumen. The Board conducted a comprehensive search to identify the right leader for Idorsia’s next phase, with a clear focus on execution, growth, and maximizing the impact of Idorsia’s innovative portfolio. Everyone is aligned on the vision to create long-term value through innovative medicines addressing significant unmet medical needs. We look forward to welcoming Roland and continuing to build on Idorsia’s strong scientific foundation, entrepreneurial culture, and ambitious future. #Idorsia #Leadership #Biopharma #Innovation #PatientFocus #Growth Read the media release: https://bit.ly/idiamr